Shared insights on the patient profile of a 75-year-old woman with multiple myeloma with confirmed lytic disease.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Extent of Prior Therapy Does Not Impact Radiotherapy Response in Myeloma
Disease control following radiotherapy appeared to be optimal in a retrospective cohort of patients with multiple myeloma.
Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
Daratumumab Combo Earns EU Approval in Newly Diagnosed Multiple Myeloma
Data from the phase 3 CEPHEUS trial support the European Commission’s approval of the daratumumab-based regimen.
Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Once-Weekly Doses of Carfilzomib Show Balanced Benefit in Real-World RRMM
A real-world analysis showed that 56 mg/m2 of carfilzomib once weekly offered many benefits over 56 mg/m2 twice weekly and 70 mg/m2 once weekly in myeloma.
Talquetamab Elicits Sustained Responses in Pre-Treated R/R Multiple Myeloma
Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.